Zhang Mei-Yin, Li Shu-Hong, Huang Guo-Liang, Lin Guo-He, Shuang Ze-Yu, Lao Xiang-Ming, Xu Li, Lin Xiao-Jun, Wang Hui-Yun, Li Sheng-Ping
State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
National Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
BMC Cancer. 2015 Feb 18;15:64. doi: 10.1186/s12885-015-1067-6.
The clinical significance of microRNAs (miRNAs) in intrahepatic cholangiocarcinoma (ICC) is unclear. The objective of this study is to examine the miRNA expression profiles and identify a miRNA signature for the prognosis of ICC.
Using a custom microarray containing 1,094 probes, the miRNA expression profiles of 63 human ICCs and nine normal intrahepatic bile ducts (NIBD) were assessed. The miRNA signatures were established and their clinical significances in ICC were analyzed. The expression levels of some miRNAs were verified by quantitative real-time RT-PCR (qRT-PCR).
Expression profile analysis showed 158 differentially expressed miRNAs between ICC and NIBD, with 77 up-regulated and 81 down-regulated miRNAs. From the 158 differentially expressed miRNAs, a 30-miRNA signature consisting of 10 up-regulated and 20 down-regulated miRNAs in ICC was established for distinguishing ICC from NIBD with 100% accuracy. A separate 3-miRNA signature was identified for predicting prognosis in ICC. Based on the 3-miRNA signature, a formula was constructed to compute a risk score for each patient. The patients with high-risk had significantly lower overall survival and disease-free survival than those with low-risk. The expression level of these three miRNAs detected by microarray was verified by qRT-PCR. Multivariate analysis indicated that the 3-miRNA signature was an independent prognostic predictor.
In this study, a 30-miRNA signature for distinguishing ICC from NIBD, and a 3-miRNA signature for evaluating prognosis of ICC were established, which might be able to serve as biomarkers for prognosis of ICC. Further studies focusing on these miRNAs may shed light on the mechanisms associated with ICC pathogenesis and progression.
微小RNA(miRNA)在肝内胆管癌(ICC)中的临床意义尚不清楚。本研究的目的是检测miRNA表达谱并确定用于ICC预后的miRNA特征。
使用包含1094个探针的定制微阵列,评估63例人类ICC和9个正常肝内胆管(NIBD)的miRNA表达谱。建立miRNA特征并分析其在ICC中的临床意义。通过定量实时RT-PCR(qRT-PCR)验证了一些miRNA的表达水平。
表达谱分析显示ICC和NIBD之间有158个差异表达的miRNA,其中77个上调,81个下调。从这158个差异表达的miRNA中,建立了一个由10个上调和20个下调的miRNA组成的30-miRNA特征,用于区分ICC和NIBD,准确率为100%。还鉴定了一个单独的3-miRNA特征用于预测ICC的预后。基于这个3-miRNA特征,构建了一个公式来计算每个患者的风险评分。高风险患者的总生存期和无病生存期明显低于低风险患者。通过qRT-PCR验证了微阵列检测到的这三种miRNA的表达水平。多变量分析表明,3-miRNA特征是一个独立的预后预测指标。
在本研究中,建立了用于区分ICC和NIBD的30-miRNA特征以及用于评估ICC预后的3-miRNA特征,它们可能作为ICC预后的生物标志物。针对这些miRNA的进一步研究可能会揭示与ICC发病机制和进展相关的机制。